Table 1.
Baseline characteristics according to TET2 mutation status.
| WT TET2 (n = 30) | Mutant TET2 (n = 11) | p-Value | |
|---|---|---|---|
| Median age | 63 (23–86) | 65 (38–82) | 0.835 |
| Sex (M/F) | 18/12 | 8/3 | 0.716 |
| Disease subtypes | 0.434 | ||
| MDS-SLD | 2 (6.7) | 0 (0.0) | |
| MDS-MLD | 6 (20.0) | 4 (36.4) | |
| MDS-EB1 | 9 (30.0) | 2 (18.2) | |
| MDS-EB2 | 8 (26.7) | 3 (27.3) | |
| MDS-U | 1 (3.3) | 0 (0.0) | |
| CMML | 4 (13.3) | 1 (9.1) | |
| 5q-syndrome | 0 (0.0) | 1 (9.1) | |
| IPSS risk categories Low Intermediate-1 Intermediate-2 High Lower-risk disease * Higher-risk disease * |
1 (3.3) 13 (43.3) 12 (40.0) 4 (13.3) 14 (46.7) 16 (53.3) |
1 (9.1) 8 (72.7) 2 (18.2) 0 (0.0) 9 (81.8) 2 (18.2) |
0.039 0.075 |
| IPSS-R risk categories Very low Low Intermediate High Very high Lower-risk group * Higher-risk group * |
1 (3.3) 3 (10.0) 6 (20.0) 9 (30.0) 11 (36.7) 10 (33.3) 20 (66.7) |
0 (0.0) 4 (36.4) 5 (45.5) 2 (18.2) 0 (0.0) 9 (81.8) 2 (18.2) |
0.009
0.006 |
| Cytogenetic abnormality | 13 (43.3) | 2 (18.2) | 0.168 |
| Cytogenetic risk categories | |||
| Very good | 2 (6.7) | 0 (0.0) | 0.102 |
| Good | 19 (63.3) | 11 (100.0) | |
| Intermediate | 2 (6.7) | 0 (0.0) | |
| Poor | 2 (6.7) | 0 (0.0) | |
| Very poor | 5 (16.7) | 0 (0.0) | |
| Lower-risk karyotype ◊ | 21 (70.0) | 11 (100.0) | 0.083 |
| Higher-risk karyotype ◊ | 9 (30.0) | 0 (0.0) | |
| Poor-risk gene mutation | 13 (43.3) | 4 (36.4) | 0.736 |
| Transfusion requirement | 26 (86.7) | 8 (72.7) | 0.361 |
Abbreviations: CMML, chronic myelomonocytic leukemia; IPSS, International Prognostic Scoring System; IPSS-R, Revised International Prognostic Scoring System; MDS-SLD, MDS-single lineage dysplasia; MDS-MLD, MDS-multilineage dysplasia; MDS-EB1, MDS-excess blasts-1; MDS-EB2, MDS-excess blasts-2; MDS-U, MDS-unclassified; TET2, Tet methylcytosine dioxygenase 2; WT, wild-type. * Based on the IPSS and IPSS-R, patients are divided into lower-risk disease (IPSS low, intermediate-1; IPSS-R very low, low, intermediate) and higher-risk disease (IPSS Intermediate-2, high; IPSS-R high, very high) groups. ◊ Based on the IPSS-R, cytogenetic risk categories are divided into lower-risk karyotype (IPSS-R very good, good) and higher-risk karyotype (IPSS-R intermediate, poor, very poor).